Dynamic Technology Lab Private LTD Rigel Pharmaceuticals Inc Transaction History

Dynamic Technology Lab Private LTD

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.12 - $1.57 $20,269 - $28,413	18,098 New	18,098 $27,000
Q3 2022 Nov 14, 2022	BUY	$1.1 - $12.2 $86,308 - $957,236	78,462 New	78,462 $93,000
Q2 2021 Aug 13, 2021	SELL	$3.09 - $4.54 $196,768 - $289,102	-63,679 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$3.35 - $4.93 $213,324 - $313,937	63,679 New	63,679 $218,000
Q3 2020 Nov 13, 2020	SELL	$1.78 - $4.13 $137,754 - $319,620	-77,390 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $109,119 - $158,649	77,390 New	77,390 $142,000
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $48,186 - $77,452	-29,562 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$2.02 - $2.61 $35,287 - $45,594	-17,469 Reduced 37.14%	29,562 $77,000
Q1 2019 May 13, 2019	BUY	$2.0 - $2.65 $22,184 - $29,393	11,092 Added 30.86%	47,031 $121,000
Q4 2018 Feb 13, 2019	BUY	$2.08 - $3.36 $20,999 - $33,922	10,096 Added 39.07%	35,939 $83,000
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $21,946 - $30,303	8,441 Added 48.51%	25,843 $83,000
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $49,247 - $71,522	17,402 New	17,402 $50,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.94B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.